FRM
CTIC

Fox Run Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Fox Run Management’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-19,263
Closed -$112K – 964
2022
Q3 		$112K Buy
+19,263
New +$120K 0.04% 542

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fox Run Management's CTIC Position: Q4 2022 in Review

Fox Run Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2022, closing a stake of 19,263 shares — an estimated $112K sold.

Fox Run Management first reported a position in CTIC in Q3 2022 and held it in 1 quarter. The position peaked at $112K in Q3 2022. 145 funds tracked by Wall St. Rank hold CTIC as of Q4 2022.

  • Fox Run Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2022 after selling out during the quarter.
  • Fox Run Management sold 19,263 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2022, an estimated $112K.
  • Fox Run Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2022 and held it in 1 quarter.
  • Fox Run Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $112K in Q3 2022.
  • 145 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2022.

Based on Fox Run Management's 13F filing for Q4 2022, filed 7 Feb 2023.